SHORT COMMUNICATION

Anti SARS-CoV2 seroprevalence in Zanzibar in 2021 before the Omicron wave

Salum Seif Salum*, Mohammed Ali Sheikhb, Antje Hebestreitc, Sørge Keld

a Department of Pathology, School of Health & Medical Sciences, State University of Zanzibar, Zanzibar Tanzania; email: salum.salum@suza.ac.tz; salummchenga@yahoo.com
b Environmental Analytical Chemistry and Eco-toxicology Lab, State University of Zanzibar, Zanzibar, Tanzania; email: m.sheikh@suza.ac.tz; sheikhmali2003@yahoo.com
c Leibniz Institute for Prevention Research and Epidemiology—BIPS, Bremen, Germany; email: hebestr@leibniz-bips.de
d Centre for Bimolecular Interactions Bremen, Faculty for Biology and Chemistry, University Bremen, Bremen, Germany; email: skelm@uni-bremen.de

* Corresponding author: Dr. Salum Seif Salum; email: salum.salum@suza.ac.tz, salummchenga@yahoo.com, mention@uni-bremen.de; postal address: School of Health & Medical Sciences, State University of Zanzibar, P.O.Box 136, Zanzibar Tanzania

Keywords
COVID-19; SARS-CoV2; Tanzania; epidemiology; cross-sectional; population-based;

Abstract
Objectives
For Tanzania including Zanzibar, The development of the COVID-19 pandemic has remained unclear, since reporting cases was suspended during2020/21. The present study provides first data on the COVID-19 seroprevalence among Zanzibari before the omicron variant wave starting in late 2021.

Design
During August through October 2021 representative cross-sectional data were collected from randomly selected households in 120 wards of the two main islands, Unguja and Pemba. Participants voluntarily provided blood samples to test their sera for antibodies against SARS-CoV2 in a semiquantitative enzyme-linked immunosorbant assay (ELISA).

Results
57% of the 2080 sera analysed were positive without significant differences between Unguja and Pemba or between rural and urban areas, similar to observations from other sub-Saharan Africa countries.

Conclusions
The antibody levels observed are most likely to previous infections with SARS-CoV2, since vaccination was basically not available before the survey. Therefore, this study provides first insight, how many Zanzibari have had COVID-19 before the Omicron variant. Further, it provides the appropriate basis for a follow-up survey addressing how this seroprevalence influenced the susceptibility to the Omicron variants, given harmonised methodologies are used.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
Background
COVID-19 was declared as a global pandemic early 2020. Following first case reports in March (WHO, 2022), Tanzania implemented protective measures. However, May 2020 Tanzania stopped reporting COVID-19 cases to WHO and most restrictions were lifted 18th May. In mid 2021 Tanzania resumed reporting, including previously detected COVID-19 cases, resulting in 33,836 confirmed cases and a death toll of 803 by 1 April 2022 (The United Republic of Tanzania, Ministry of Health, 2022). These data clearly show COVID-19 waves for April-June 2020, January-March 2021, June-August 2021 coinciding with the original, alpha and delta variants waves, as well as for omicron variants, December 2021 through March 2022, (The United Republic of Tanzania, Ministry of Health, 2022).

Herd (or population) immunity is achieved, if a sufficient proportion of a population has acquired immunity, through natural infection or vaccination, to prevent further spread of the pathogen. To achieve this for COVID-19, vaccination is the most efficient and preferred way, according to WHO (WHO, 2020), although the proportion that must be vaccinated to effect herd immunity is still not known. While several efficient vaccines have been produced, in most sub-Saharan Africa countries these have only become available late and in low numbers. Zanzibar began vaccination July 2021 (Mikofu, 2021) and vaccination coverage in Tanzania including Zanzibar is still around 5% (The United Republic of Tanzania, Ministry of Health, 2022).

While confirmed COVID-19 cases correspond to only 0.5% of the population, an unknown number of SARS-CoV2 infections must be expected. Seroprevalence of anti-SARS-CoV2 antibodies can provide essential information (Bobrovitz et al., 2021). Therefore, this study was performed in 2021 providing first data of the COVID-19 seroprevalence among Zanzibari before the omicron variants wave started in November 2021.

Methods
Study area, study design and sampling
This cross-sectional study was designed to provide representative seroprevalence data from the main islands, Unguja and Pemba. 120 of the total 388 wards (Shehias) were randomly selected covering urban and rural areas. 354 randomly selected households were visited from 28th July through 20th October 2021. All household members were enrolled, irrespective of their age or sex, as in a previous survey (Nyangasa et al., 2016). All eligible participants gave written consent in an entirely voluntary manner after all relevant information had been provided in the local language.

Venous blood samples were collected into clotting activation tubes and transported to the laboratory for processing. Following centrifugation serum was stored at -80°C.

Laboratory Analysis
The EUROIMMUN Anti-SARS-CoV-2 ELISA (IgG) kit provided a semi-quantitative analysis detecting human IgG antibodies against S1 domain of SARS-CoV-2 spike protein indicating prior infections and has been recommended for seroprevalence surveys like this (Gededzha et al., 2021). Using the calibrator of the kit, a ratio-based analysis (OD of sample/OD of calibrator) of the obtained data was performed to differentiate between negative (ratio below 0.8), positive (ratio above 1.1) and borderline cases. According to the manufacturer’s information, this kit displayed a positive agreement of 90% (95%CI=73.5%-97.9%), counting borderlines as negative, and a negative agreement of 100.0% (95%CI=95.5%-100.0%).

Results and Discussion
Until now, the frequency of SARS-CoV-2 infections causing COVID-19 in Tanzania has been unknown. Seroprevalence provides important information how many individuals were exposed to SARS-CoV-2 before sampling. This study is the first report on anti-SARS-CoV-2 sero-
prevalence in Zanzibar population. In total, 2,080 participants (66.2% of 3,143) from 349 (98.6%) households of this survey provided blood samples, with 2,054 serum samples being tested for anti-SARS-CoV-2 IgG; 57% of these samples were positive. Since vaccination against Covid-19 basically had not been available to participants, the antibodies detected are likely to be induced by preceding SARS-CoV-2 infection(s) during COVID-19 waves (The United Republic of Tanzania, Ministry of Health, 2022).

Seroprevalence was relatively evenly distributed and only minor differences were observed (Table 1) without significant differences between Unguja and Pemba. On Unguja, the seroprevalence observed in urban districts Magharibi and Mjini was lower, whereas on Pemba the lowest was in Micheweni, a rural district (Table 1). Prevalence was slightly higher in males compared to the female participants. The highest seroprevalence was observed in adolescents (Table 2).

In summary, this first population-based survey uncovered widespread SARS-CoV-2 seropositivity across all districts of Zanzibar prior to the onset of the current Omicron-dominated wave. Overall, seroprevalences observed are similar to those observed in other sub-Saharan Africa countries (Lewis et al., 2022).

At present, this level of seroprevalence cannot be considered as herd immunity, since it is uncertain, how antibody levels correlate with virus neutralisation, protection against re-infection, symptomatic and asymptomatic cases (Centers for Disease Control and Prevention, 2020, Hamady et al., 2022). In this respect, comparing the seroprevalences reported here with the current situation after/during the Omicron variants wave could provide important information, if using identical tools complementing the analysis with neutralising activities against Omicron and previous variants in these sera.

Conflict of interest
All authors declare that they don’t have a conflict of interest regarding the publication of this study.

Funding sources
Financial support has been provided by Deutscher Akademischer Austauschdienst (DAAD, PAGEL program, project MENTION to SK, University Bremen, and SSS, State University Zanzibar) and EU (Erasmus+ International mobility program to University Bremen). The funding agencies had no influence on the study design, collection, analysis or interpretation of the data; they were not involved on the decision to submit the manuscript.

Ethical approval statement
The study has been carried out in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki) for experiments involving humans and was approved by The Second Vice President Office and The Ministry of Health Zanzibar through the Zanzibar Medical Research and Ethics Committee (ZAMREC/0001/AUGUST/013).

Acknowledgement
Authors are grateful to all participants for their invaluable contribution as well as to all Shehas of the participating wards for their the support. We highly appreciate the restless technical support by Petra Berger and all members of the Unguja and Pemba survey teams. The authors acknowledge very much the efforts of the Public Health Laboratory, Pemba, the Zanzibar Health Research Institute, and the Ministry of Health for their essential support, which they devoted for successful completion of this study.
References


### Table 1. Regional seroprevalences; total number of tests conducted in Unguja and Pemba and their respective districts with seropositivity in percent.

<table>
<thead>
<tr>
<th>District</th>
<th>Seropositive (N [%])</th>
<th>Seronegative (N [%])</th>
<th>Borderline (N [%])</th>
<th>Total (N)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total (Unguja)</td>
<td>775 [57.2%]</td>
<td>486 [35.9%]</td>
<td>94 [6.9%]</td>
<td>1355</td>
</tr>
<tr>
<td>Total (Pemba)</td>
<td>395 [56.5%]</td>
<td>267 [38.2%]</td>
<td>37 [5.3%]</td>
<td>699</td>
</tr>
<tr>
<td>Kaskazini A (Unguja)</td>
<td>84 [56.8%]</td>
<td>53 [35.8%]</td>
<td>11 [7.4%]</td>
<td>148</td>
</tr>
<tr>
<td>Kaskazini B (Unguja)</td>
<td>91 [61.9%]</td>
<td>49 [33.3%]</td>
<td>7 [4.8%]</td>
<td>147</td>
</tr>
<tr>
<td>Kati (Unguja)</td>
<td>161 [58.5%]</td>
<td>93 [36.0%]</td>
<td>21 [4.3%]</td>
<td>275</td>
</tr>
<tr>
<td>Kusini (Unguja)</td>
<td>83 [59.7%]</td>
<td>50 [36.0%]</td>
<td>6 [4.3%]</td>
<td>139</td>
</tr>
<tr>
<td>Magharibi (Unguja)</td>
<td>160 [53.5%]</td>
<td>122 [40.8%]</td>
<td>17 [5.7%]</td>
<td>299</td>
</tr>
<tr>
<td>Mjini (Unguja)</td>
<td>196 [56.5%]</td>
<td>34.3 [35.0%]</td>
<td>32 [9.2%]</td>
<td>347</td>
</tr>
<tr>
<td>Chake (Pemba)</td>
<td>113 [60.8%]</td>
<td>59 [31.7%]</td>
<td>14 [7.5%]</td>
<td>186</td>
</tr>
<tr>
<td>Micheweni (Pemba)</td>
<td>85 [50.6%]</td>
<td>74 [44.0%]</td>
<td>9 [5.4%]</td>
<td>168</td>
</tr>
<tr>
<td>Mkoani (Pemba)</td>
<td>127 [56.2%]</td>
<td>89 [39.4%]</td>
<td>10 [3.4%]</td>
<td>226</td>
</tr>
<tr>
<td>Wete (Pemba)</td>
<td>70 [58.8%]</td>
<td>45 [37.8%]</td>
<td>4 [3.4%]</td>
<td>119</td>
</tr>
</tbody>
</table>

### Table 2. Sex and age distribution of seroprevalences; total number and percentage of tests conducted.

<table>
<thead>
<tr>
<th>Population tested</th>
<th>Seropositive (N [%])</th>
<th>Seronegative (N [%])</th>
<th>Borderline (N [%])</th>
<th>Total (N)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Female</td>
<td>625 [56.0%]</td>
<td>417 [37.4%]</td>
<td>74 [6.6%]</td>
<td>1116</td>
</tr>
<tr>
<td>Male</td>
<td>544 [58.1%]</td>
<td>336 [35.9%]</td>
<td>57 [6.1%]</td>
<td>937</td>
</tr>
<tr>
<td>age group 5 - &lt;10 years</td>
<td>136 [54.6%]</td>
<td>98 [39.4%]</td>
<td>15 [6.0%]</td>
<td>249</td>
</tr>
<tr>
<td>age group 10 - &lt;14 years</td>
<td>171 [61.5%]</td>
<td>97 [34.9%]</td>
<td>10 [3.6%]</td>
<td>278</td>
</tr>
<tr>
<td>age group 14 - &lt;17 years</td>
<td>122 [66.7%]</td>
<td>49 [26.8%]</td>
<td>12 [6.6%]</td>
<td>183</td>
</tr>
<tr>
<td>age group 17 - &lt;60 years</td>
<td>600 [55.0%]</td>
<td>410 [37.6%]</td>
<td>81 [7.4%]</td>
<td>1091</td>
</tr>
<tr>
<td>age group &gt;60 years</td>
<td>122 [59.2%]</td>
<td>72 [35.0%]</td>
<td>12 [5.8%]</td>
<td>206</td>
</tr>
<tr>
<td>Total population</td>
<td>1170 [57.0%]</td>
<td>753 [36.7%]</td>
<td>131 [6.4%]</td>
<td>2054</td>
</tr>
</tbody>
</table>